vTv Therapeutics Inc.
VTVTHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, vTv Therapeutics Inc. focuses on Biotechnology services and products. vTv Therapeutics Inc. vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. The $129.6M market capitalization puts VTVT squarely in micro-cap range for its industry. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Market Cap
$129.6M
Beta
0.25
P/E (TTM)
—
P/E (Fwd)
-8.46
EPS (TTM)
$-0.77
EPS (Fwd)
$-3.89
ROE
-1.5%
ROA
-2.9%
Cash
$98.1M
Total Debt
$0
Free CF
$5.3M
52W Change
93.3%
Annual Financials
Cash vs Debt
Where VTVT stands vs its 150-day and 200-day moving averages
As of the July 10, 2026 close, VTVT finished 5.05% below its 150-day moving average ($35.22) and 2.83% above its 200-day moving average ($32.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VTVT overbought or oversold?
At the July 10, 2026 close, VTVT's RSI(14) was 48.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
vTv Therapeutics Inc. reports $98.1M in cash and $0 in total debt. Annual free cash flow of $5.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -1.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.0M (2021) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.25 suggests VTVT is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for vTv Therapeutics Inc. and its sector.